230 related articles for article (PubMed ID: 35138582)
21. Avoiding Unnecessary Biopsy after Multiparametric Prostate MRI with VERDICT Analysis: The INNOVATE Study.
Singh S; Rogers H; Kanber B; Clemente J; Pye H; Johnston EW; Parry T; Grey A; Dinneen E; Shaw G; Heavey S; Stopka-Farooqui U; Haider A; Freeman A; Giganti F; Atkinson D; Moore CM; Whitaker HC; Alexander DC; Panagiotaki E; Punwani S
Radiology; 2022 Dec; 305(3):623-630. PubMed ID: 35916679
[TBL] [Abstract][Full Text] [Related]
22. Is it necessary for all patients with suspicious lesions undergo systematic biopsy in the era of MRI-TRUS fusion targeted biopsy?
Lv Z; Wang J; Wang M; Hou H; Song L; Li H; Wang X; Liu M
Int Braz J Urol; 2023; 49(3):359-371. PubMed ID: 37115180
[TBL] [Abstract][Full Text] [Related]
23. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
[No Abstract] [Full Text] [Related]
24. Characterizing indeterminate (Likert-score 3/5) peripheral zone prostate lesions with PSA density, PI-RADS scoring and qualitative descriptors on multiparametric MRI.
Brizmohun Appayya M; Sidhu HS; Dikaios N; Johnston EW; Simmons LA; Freeman A; Kirkham AP; Ahmed HU; Punwani S
Br J Radiol; 2018 Feb; 91(1083):20170645. PubMed ID: 29189042
[TBL] [Abstract][Full Text] [Related]
25. Prediction of Significant Prostate Cancer in Equivocal Magnetic Resonance Imaging Lesions: A High-volume International Multicenter Study.
Sigle A; Borkowetz A; von Hardenberg J; Drerup M; Kornienko K; Kwe J; Wenzel M; Mandel P; Westhoff N; Rieger C; Hoffmann MA; Ortner G; Mahjoub S;
Eur Urol Focus; 2023 Jul; 9(4):606-613. PubMed ID: 36804191
[TBL] [Abstract][Full Text] [Related]
26. Multivariable stratification of PI-RADS version 2.1 categories for the risk of false-positive target biopsy: Impact on prostate biopsy decisions.
Girometti R; Giannarini G; De Martino M; Caregnato E; Cereser L; Soligo M; Rozze D; Pizzolitto S; Isola M; Zuiani C
Eur J Radiol; 2023 Aug; 165():110897. PubMed ID: 37300933
[TBL] [Abstract][Full Text] [Related]
27. Low cancer yield in PI-RADS 3 upgraded to 4 by dynamic contrast-enhanced MRI: is it time to reconsider scoring categorization?
Messina E; Pecoraro M; Laschena L; Bicchetti M; Proietti F; Ciardi A; Leonardo C; Sciarra A; Girometti R; Catalano C; Panebianco V
Eur Radiol; 2023 Aug; 33(8):5828-5839. PubMed ID: 37045981
[TBL] [Abstract][Full Text] [Related]
28. Which men with non-malignant pathology at magnetic resonance imaging-targeted prostate biopsy and persistent PI-RADS 3-5 lesions should repeat biopsy?
Castellani D; Pace G; Cecchini S; Franzese C; Cicconofri A; Romagnoli D; Del Rosso A; Possanzini M; Paci E; Dellabella M; Pierangeli T
Urol Oncol; 2022 Oct; 40(10):452.e9-452.e16. PubMed ID: 35871992
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic Accuracy and Prognostic Value of Serial Prostate Multiparametric Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer.
Chu CE; Cowan JE; Lonergan PE; Washington SL; Fasulo V; de la Calle CM; Shinohara K; Westphalen AC; Carroll PR
Eur Urol Oncol; 2022 Oct; 5(5):537-543. PubMed ID: 33483265
[TBL] [Abstract][Full Text] [Related]
30. Prostate imaging-reporting and data system version 2 in combination with clinical parameters for prostate cancer detection: a single center experience.
Wang L; Luo Y; Liu T; Deng M; Huang X
Int Urol Nephrol; 2023 Jul; 55(7):1659-1664. PubMed ID: 37171702
[TBL] [Abstract][Full Text] [Related]
31. Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate.
Boschheidgen M; Schimmöller L; Doerfler S; Al-Monajjed R; Morawitz J; Ziayee F; Mally D; Quentin M; Arsov C; Albers P; Antoch G; Ullrich T
Sci Rep; 2022 Apr; 12(1):6746. PubMed ID: 35469056
[TBL] [Abstract][Full Text] [Related]
32. Avoiding unnecessary biopsy: the combination of PRIMARY score with prostate-specific antigen density for prostate biopsy decision.
Guo S; Zhang J; Wang Y; Jiao J; Li Z; Cui C; Chen J; Yang W; Ma S; Wu P; Jing Y; Wen W; Kang F; Wang J; Qin W
Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):288-293. PubMed ID: 38160227
[TBL] [Abstract][Full Text] [Related]
33. Prostate cancer detection on transrectal ultrasonography-guided random biopsy despite negative real-time magnetic resonance imaging/ultrasonography fusion-guided targeted biopsy: reasons for targeted biopsy failure.
Cash H; Günzel K; Maxeiner A; Stephan C; Fischer T; Durmus T; Miller K; Asbach P; Haas M; Kempkensteffen C
BJU Int; 2016 Jul; 118(1):35-43. PubMed ID: 26384851
[TBL] [Abstract][Full Text] [Related]
34. Should Targeted Biopsy be Performed in Patients Who Have Only Pi-rads 3 Lesions?
Koparal MY; Sözen TS; Karşiyakali N; Akdoğan B; Özen H; Aslan G; Türkeri L
Arch Esp Urol; 2022 Jun; 75(5):410-415. PubMed ID: 35983811
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic value of combining PI-RADS v2.1 with PSAD in clinically significant prostate cancer.
Wei X; Xu J; Zhong S; Zou J; Cheng Z; Ding Z; Zhou X
Abdom Radiol (NY); 2022 Oct; 47(10):3574-3582. PubMed ID: 35788882
[TBL] [Abstract][Full Text] [Related]
36. Value of 3-Tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance.
Pessoa RR; Viana PC; Mattedi RL; Guglielmetti GB; Cordeiro MD; Coelho RF; Nahas WC; Srougi M
BJU Int; 2017 Apr; 119(4):535-542. PubMed ID: 27500389
[TBL] [Abstract][Full Text] [Related]
37. A combined MRI-PSAD risk stratification system for prioritizing prostate biopsies.
Bar-Yaakov N; Savin Z; Fahoum I; Barnes S; Bar-Yosef Y; Yossepowitch O; Keren-Paz G; Mano R
Can J Urol; 2024 Feb; 31(1):11793-11801. PubMed ID: 38401259
[TBL] [Abstract][Full Text] [Related]
38. Repeat MRI during active surveillance: natural history of prostatic lesions and upgrading rates.
Luzzago S; Piccinelli ML; Mistretta FA; Bianchi R; Cozzi G; Di Trapani E; Cioffi A; Catellani M; Fontana M; Jannello LMI; Botticelli FMG; Marvaso G; Alessi S; Pricolo P; Ferro M; Matei DV; Jereczek-Fossa BA; Fusco N; Petralia G; de Cobelli O; Musi G
BJU Int; 2022 Apr; 129(4):524-533. PubMed ID: 34687137
[TBL] [Abstract][Full Text] [Related]
39. The Value of Prostate-specific Antigen Density for Prostate Imaging-Reporting and Data System 3 Lesions on Multiparametric Magnetic Resonance Imaging: A Strategy to Avoid Unnecessary Prostate Biopsies.
Görtz M; Radtke JP; Hatiboglu G; Schütz V; Tosev G; Güttlein M; Leichsenring J; Stenzinger A; Bonekamp D; Schlemmer HP; Hohenfellner M; Nyarangi-Dix JN
Eur Urol Focus; 2021 Mar; 7(2):325-331. PubMed ID: 31839564
[TBL] [Abstract][Full Text] [Related]
40. Risk Stratification Among Men With Prostate Imaging Reporting and Data System version 2 Category 3 Transition Zone Lesions: Is Biopsy Always Necessary?
Felker ER; Raman SS; Margolis DJ; Lu DSK; Shaheen N; Natarajan S; Sharma D; Huang J; Dorey F; Marks LS
AJR Am J Roentgenol; 2017 Dec; 209(6):1272-1277. PubMed ID: 28858541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
